IVAC-led study publishes landmark results

Explore a visualization of the PERCH results.

Updates

Four takeaways from iHEA 2019, a Swiss summit on health economics

August 2019

Last month, representatives from the IVAC Economics and Finance (E&F) team attended the International Health Economics Association (iHEA) Congress in Basel, Switzerland. As new members of Immunization Economics, a specialized group of economists working on immunization, Bryan Patenaude, Cristina Garcia, Gatien de Broucker, and Elizabeth (Libby) Watts had several significant contributions to the biannual conference. […]

IVAC-led PERCH study reveals viruses as new leading cause of global childhood pneumonia

June 2019

Respiratory syncytial virus (RSV) and other viruses now appear to be the main causes of severe childhood pneumonia in low- and middle-income countries, highlighting the need for vaccines against these pathogens, according to a study from a consortium of scientists from around the world led by the International Vaccine Access Center in the Johns Hopkins Bloomberg School of Public Health.

Opinion: 10 signs we’re winning the fight against pneumococcal disease

May 2019

During World Immunization Week, I’ve been reflecting on a major milestone: It’s been 10 years since the first low-income country, Rwanda, introduced pneumococcal conjugate vaccine into its infant immunization schedule.

Digital Tools

IVAC’s digital platforms contain downloadable vaccine introduction maps, messaging compendiums, advocacy guides, and more.

Where We Work

IVAC works with governments and major research institutions in 38 countries

What We Do: Project highlights

The Pneumonia Etiology Research for Child Health (PERCH) study

The Pneumonia Etiology Research for Child Health (PERCH) study is a case-control study led by IVAC that enrolled 4,232 cases and 5,325 controls between 2011-2014 at 9 sites in 7 countries (The Gambia, Mali, Kenya, Zambia, South Africa, Bangladesh and Thailand). Read More >

Rotavirus Accelerated Vaccine Introduction Network (RAVIN)

The Rotavirus Accelerated Vaccine Introduction Network (RAVIN) is a partnership led by Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center (IVAC), in collaboration with JSI and CDC, and is designed to provide policy, advocacy, and technical support to focus countries throughout the entire continuum of introducing rotavirus vaccine (RVV) – from the consideration and decision-making process to implementation and post-launch activities. Read More >

More Highlights